603259 Share Price Performance
CN¥0
-60.45 (-100.00%)
Price CN¥0
Fair ValueCN¥137.83
Share Pricen/a
WuXi AppTec Co., Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
603259 Community Narratives
AN
Fair Value
·Fair Value CN¥137.83 19.3% undervalued intrinsic discount
Upcoming Meetings and Capital Moves Will Drive Long-Term Opportunities
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value CN¥152 26.9% undervalued intrinsic discount
Global Aging And Advanced Therapies Will Expand Outsourcing
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value CN¥114.8 3.2% undervalued intrinsic discount
Rising Geopolitical And Regulatory Pressures Will Crash Profits
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Upcoming Meetings and Capital Moves Will Drive Long-Term Opportunities
Key Takeaways Enhanced service capabilities and global expansion drive resilient, diversified revenue streams and margin growth, supporting long-term profit stability. Strong order backlog and rising demand for pharmaceutical outsourcing boost high-value project ramp-up, ensuring future revenue growth and customer retention.Read more
AN
CN¥137.83
19.3% undervalued intrinsic discount
Fair Value
Revenue
15.57% p.a.
Profit Margin
30.57%
Future PE
27.06x
Price in 2029
CN¥171.63
Rising Geopolitical And Regulatory Pressures Will Crash Profits
Key Takeaways Geopolitical tensions, protectionism, and stricter regulations jeopardize global customer access, threaten revenue growth, and cause operational uncertainty. Regionalized supply chains, overexpansion risks, and mounting domestic competition compress margins and threaten long-term profitability.Read more
AN
CN¥114.8
3.2% undervalued intrinsic discount
Fair Value
Revenue
16.4% p.a.
Profit Margin
30.86%
Future PE
23.26x
Price in 2029
CN¥143.02
Global Aging And Advanced Therapies Will Expand Outsourcing
Key Takeaways Rapid operational scaling, advanced technology investments, and global expansion drive WuXi AppTec's market share gains, margin outperformance, and recurring earnings stability over time. Deepening long-term pharma partnerships, increased project complexity, and sector consolidation position the company for durable growth and resilience against industry cyclicality.Read more
AN
CN¥152
26.9% undervalued intrinsic discount
Fair Value
Revenue
20.06% p.a.
Profit Margin
33.9%
Future PE
25.51x
Price in 2029
CN¥189.15
Trending Discussion
Recently Updated Narratives
AN
603259: APAC Conviction List Inclusion Will Support Long Term Upside
Fair Value: CN¥137.83 19.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
603259: Conviction List Inclusion And 2026 Guidance Will Shape Balanced Outlook
Fair Value: CN¥114.8 3.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
603259: Higher Margins And New Guidance Are Expected To Support Future Earnings
Fair Value: CN¥152 26.9% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
WuXi AppTec Co., Ltd. Key Details
About 603259
- Founded
- 2000
- Employees
- 33834
- CEO
- WebsiteView website
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People’s Republic of China.
